Bruntwood and Legal & General Capital have established a partnership to create the UK’s largest property platform dedicated to driving science and technology growth in regional cities. The deal will see the two partners invest £360m ($472m) of capital, property and intellectual assets into a new company, Bruntwood SciTech, with a business plan supporting the creation of over 20,000 high value jobs. The deal represents the largest investment made in science and technology property assets in Europe this year. Bruntwood SciTech’s portfolio is already home to more than 500 science and technology businesses, ranging from digital start-ups to global life sciences companies. It is centred around flagship assets and development projects in Manchester, Birmingham and Leeds, and includes the internationally-recognised life science campus in Cheshire, Alderley Park. The major life science asset within the portfolio, Alderley Park, is already the subject of a £160m ($210m) development vision. It is now home to 65 SMEs and 150 start-ups and is further focussed on forming, growing and scaling life science sector businesses. Alderley Park has two venture funds on site, one of which, the £42m Greater Manchester and Cheshire Life Science Fund has already invested in 25 businesses across pharmaceuticals, biotech, diagnostics, CROs and medical devices. It also serves as the headquarters of the Medicines Discovery Catapult, which is focussed on bringing new proven therapies to patients faster and more cost-effectively, and the AMR Centre, a leader in the UK’s response to the global health crisis posed by antibiotic resistance. Bruntwood SciTech will also develop and be home to a new precision medicine campus within Manchester’s Oxford Road Corridor Enterprise Zone. Leveraging its position on Europe’s largest clinical-academic campus the £60m expansion of Citylabs will be the heart of the new cluster and occupied by global diagnostics company QIAGEN. The expanded campus will also complement the pioneering work by industry and the NHS in Greater Manchester to integrate electronic health data with genomic technology. The new business will be chaired by Bruntwood Chief Executive Chris Oglesby. He commented: “Life science is central to the UK government’s Industrial Strategy - the first to get a sector deal and one with a track record of innovation that marks it out as world class. Life science already contributes more than £10.8 billion ($14 billion) a year to the UK economy... Bruntwood SciTech will be front and centre when it comes to pushing the sector forward”.
Alderley Park, Cheshire, UK.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.